BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  Kite Helps Fund American Cancer Society’s Expanded Efforts to Advance Innovation and Improve Support for People Facing Blood Cancers

  June 25, 2026

   · 

  3 min read
• Press Releases

  Clinilabs Announces New Affiliation With Rutgers University

  June 25, 2026

   · 

  3 min read
• Press Releases

  GRAIL Completes $110 Million Equity Financing With Samsung Entities

  June 25, 2026

   · 

  9 min read
• Press Releases

  Molecular Instruments Advances Automated Multiplex Tissue Research with HCR™ Gold IF on the BOND RX Research Staining Instrument

  June 25, 2026

   · 

  3 min read
• 

  Mergers & acquisitions

  BIO 2026: Forget dual track—biopharma deals are more complex than ever

  Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.

  June 25, 2026

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  FDA

  BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year

  Policymaking at FDA has been anything but business as usual under the Trump administration, but former regulators cite the agency’s new investigational new drug pilot program as a sign of normalcy.

  June 25, 2026

   · 

  3 min read

   · 

  Jef Akst
• Press Releases

  Gazyva® (obinutuzumab) receives positive reimbursement recommendation from the Institut national d’excellence en santé et en services sociaux (INESSS) for persons with active lupus nephritis

  June 25, 2026

   · 

  6 min read
• Press Releases

  Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer

  June 25, 2026

   · 

  6 min read
• Press Releases

  Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

  June 25, 2026

   · 

  2 min read
• Press Releases

  Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria

  June 25, 2026

   · 

  7 min read